According to IMS data, the global anti-cancer drug market increased from 91 billion US dollars in 2012 to 116 billion US dollars in 2016; China's anti-tumor market increased from 60.4 billion yuan in 2012 to 126.8 billion yuan in 2017, and the market size is expected to be 2018. It reached 144.7 billion yuan. It is understood that in recent years, the scale of China's anti-tumor drug market has continued to expand, and more and more companies have joined in the research and development of innovative drugs such as anti-tumor drugs, especially the research and development of PD-1/PD-L1 antibodies.
In recent years, China has continuously encouraged the development of anticancer drugs in its policies, such as implementing zero tariffs on 28 kinds of drugs including anticancer drugs and promoting the inclusion of anticancer drugs in medical insurance catalogues. With huge market demand and favorable policies, major companies have begun to actively deploy their own cancer drug pipelines.
According to relevant statistics, there are currently 88 anti-cancer concept stocks, including Hengrui Medicine, Fosun Pharma, Beida Pharmaceutical, Kelun Pharmaceutical, Shijiazhuang Group, and Shanghai Pharmaceutical. It is reported that since September, some pharmaceutical companies in China have also made some breakthroughs in anticancer drugs.
Hengrui's anti-tumor innovative drug Ai Ruini was approved for listing. On September 12, a new generation of targeted drugs for the treatment of HER2-positive advanced breast cancer, developed by Hengrui Medicine, has a clear clinical value and has been included in the list of priority review products by the State Drug Administration. And obtain conditional approval for listing. It is reported that this is the first anti-tumor drug approved for the market based on the results of Phase II clinical studies in Chinese solid tumors.
The successful listing of Ai Ruini shows that the national pharmaceutical enterprises represented by Hengrui Medicine are gradually completing the transformation from imitation to innovation. It is understood that Hengrui Medicine has always been committed to innovation and research and development. The annual R&D investment accounts for more than 10% of its operating income. In the past 10 years, Hengrui Medicine has undertaken 30 major special projects, obtained 6 new drug certificates and generated approval documents, and 2 A new class 1 drug has been declared for production.
Shanghai Pharmaceuticals is holding hands with Ross brand pharmaceutical companies to produce and sell anti-tumor drugs. Zhou Jun, Chairman of Shanghai Pharmaceuticals and Morozov, founder and CEO of Russian BIOCAD Biopharmaceuticals, officially signed a memorandum of cooperation intention on September 12 when the 4th Far East Economic Forum was held in Vladivostok, Russia. The two parties agreed to jointly establish two joint ventures in China to carry out localized production of macromolecular anti-tumor drugs, as well as import registration and sales.
It is reported that the first phase of the cooperation products will include 4 heavy biosimilars and 2 bio-innovative drugs owned by BIOCAD, mainly for the treatment of breast cancer, gastric cancer, non-Hodgkin's lymphoma, chronic lymphatic leukemia, non-small cell lung cancer. , cervical cancer and rheumatoid arthritis and other diseases.
The drug for the treatment of colorectal cancer developed by Hutchison Whampoa was approved for marketing. On September 5, the State Drug Administration issued a notice stating that the drug for the treatment of metastatic colorectal cancer, furazolinib (Aiyoute), was marketed for the previous treatment of fluorouracil, oxaliplatin and irinotecan. Based chemotherapy, and patients with metastatic colorectal cancer who have previously received or are not eligible for anti-vascular endothelial growth factor (VEGF) therapy, anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). It is worth mentioning that furofinib capsule is an innovative drug that is not listed at home or abroad. It is a new type of targeted anti-tumor drug developed by Chinese local enterprises with complete intellectual property rights.
Fruquintinib (HMPL-013) is a targeted cancer treatment drug independently developed by Huang Medicine. It is a quinazoline small molecule angiogenesis inhibitor. The main target is the VEGFR kinase family (VEGFR1, 2 and 3).
With the support of the speed-up of new drug listing approval and the speed of approval of imported drugs, since 2008, 8 new anti-cancer drugs/imported drugs have been approved for listing in China. The anti-cancer market has broad prospects, and the scale of the anti-cancer drug market is also expanding. More and more pharmaceutical companies are entering this market. However, some experts in the industry have reminded that although anti-tumor drugs are hot spots in recent years, they have long research and development cycles, high failure rates, and large investment. Enterprises must be cautious in entering the market. Do not blindly follow the "hot spots". Make an investment. For unlisted innovative pharmaceutical companies, it is necessary to solve the problem of sustainable investment in the high-investment period of anti-tumor drugs.
Sofa Sets,sofa set for living room,recliner sofa set,leather sofa set
Guangzhou LoPhiDa Co.Ltd , https://www.widinlsamachine.com